Drugs Manufactured With A Forged License, FIR Lodged, Drugs Worth 23.93 Lakhs Seized

Hyderabad: Drugs Control Administration, Telangana, has detected a significant case of fraudulent activity within the pharmaceutical industry. An investigation conducted by DCA officials has revealed that Ovoid Pharmachem Pvt. Ltd., located at Plot No. 318, Subashnagar, Quthbullapur Mandal, Medchal-Malkajgiri District, engaged in the forgery of a drug manufacturing license.

VB Kamalasan Reddy (IPS), Director General, DCA Telangana said in a press release that “Narasapally Ramudu, Director of Ovoid Pharmachem Pvt. Ltd., was involved in the creation of a forged Drug Manufacturing license in Form-25, bearing No. TS/MFG2019-43319, L.Dis.No: 315995/TS/2022 dated: 05/07/2022, for certain drug products which were not authorized for the company by the Drugs Control Administration, Telangana. This unlawful activity was carried out with the intention to deceive drug regulatory authorities, pharmaceutical manufacturers, distributors, and the public.

Upon verification of the Drugs Control Administration, Telangana licensing database on the ODLS (Online Drug Licensing System) Portal, it has been confirmed that Ovoid Pharmachem Pvt. Ltd. created a fake drug licence for certain drug products.

DCA also detected that the firm manufactured and sold certain drug products under this fraudulent license. Drugs Control Administration officials seized stocks worth Rs. 23.93 lakhs, including 800 Kgs of Activated Charcoal 250 mg and Simethicone 80 mg Pellets.”

Drugs Control Administration, Telangana, has filed a complaint with the Jeedimetla Police Station. FIR No. 327/2024 has been registered on 05-04-2024 against Mr. Narasapally Ramudu, Director of Ovoid Pharmachem Pvt. Ltd., under Sections 420 (Cheating) and 468 (Forgery) of the Indian Penal Code (IPC).

It is imperative to emphasize that the manufacturing and sale of pharmaceutical products under forged licenses pose a significant threat to public health and safety. All manufacturers shall comply strictly with regulatory requirements and maintain the highest standards of ethical conduct.

Related Posts

  • Pharma
  • July 26, 2024
  • 116 views
US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

Maryland: The US Food and Drug Administration (FDA) has warned Brassica Pharma for numerous good manufacturing practice (GMP) violations, including multiple instances of employees falsifying sterility and environmental monitoring data and…

  • Pharma
  • July 26, 2024
  • 108 views
Indian National Charged With Selling Counterfeit Cancer Drugs

HOUSTON: A federal grand jury has returned an indictment charging an Indian national with selling and shipping tens of thousands of dollars in counterfeit oncology pharmaceuticals into the United States,…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

Indian National Charged With Selling Counterfeit Cancer Drugs

Indian National Charged With Selling Counterfeit Cancer Drugs

ICMR Releases 32 New Treatment Standards For Treating Common And Serious Diseases

ICMR Releases 32 New Treatment Standards For Treating Common And Serious Diseases

BIS Sanctioned 82 Medical Device Projects To Develop Standards

BIS Sanctioned 82 Medical Device Projects To Develop Standards

Anti-Narcotics Task Force Will Be Formed Soon In Rajasthan: HM

Anti-Narcotics Task Force Will Be Formed Soon In Rajasthan: HM

‘Sunrise’ MedTech Industry in India & ‘Clouds’ strangling it, Brainstormed in PHD

‘Sunrise’ MedTech Industry in India & ‘Clouds’ strangling it, Brainstormed in PHD